Life Science and pharmaceutical company, CanaQuest, has signed an agreement for an educational partnership with the Canadian Cannabis Dispute Resolution Centre.
CanaQuest, which develops health products utilising cannabinoid molecules and other pharmaceutical grade botanical compounds, has announced its new partnership with the Canadian Cannabis Dispute Resolution Centre (CCDRC), a national organisation that has developed cannabis-related education and training programmes, both domestically and internationally, to assist different levels of government, the private sector, industry-specific organisations, and associations.
The CCDRC/CanaQuest partnership will serve to raise global awareness of medical cannabis, and the common theme of all education relates to conflict resolution, which can be mitigated through education.
Education and consulting services
A critical component of the partnership will be its focus on promoting scientifically backed evidence, pre-clinical data, and published research papers of Dr Steven Laviolette and his 13-person team at Western University in Canada.
For the past 20 years, Dr Laviolette and team have studied the effects of cannabinoids on mental health and wellness. Their research focuses on using cannabinoids for the development of novel pharmacotherapies to address anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder (PTSD).
Treena Reilkoff, a Trauma Informed Mediator and Facilitator with the CCDRC, said: “We are pleased to have the opportunity to collaborate with CanaQuest. Our common goal is the recognition that medicinal cannabis is an alternative treatment to traditional pharmaceuticals and through education about the practicality and safety of medicinal cannabis, barriers, and stigmas are reduced. The CCDRC is pleased to provide education and consulting services to help prevent cannabis-related workplace conflicts from escalating.”
Paul Ramsay, CanaQuest Co-founder and President, added: “Our joint recognition of the importance of education and of people being able to have self-determination in their choices of prescriptions are the key drivers of this partnership.”
